US stock · Healthcare sector · Medical Devices
Company Logo

DexCom, Inc.

DXCMNASDAQ

281.32

USD
-6.81
(-2.36%)
Pre Market
143.82P/E
61Forward P/E
5.55P/E to S&P500
27.605BMarket CAP
- -Div Yield
Upcoming Earnings
27 Jul-1 Aug
Shares Short
4/29/22
3.34M
Short % of Float
3.82%
Short % of Shares Outs.
3.40%
% Held by Insiders
0.40%
% Held by Institutions
98.56%
Beta
0.93
PEG Ratio
2.76
52w. high/low
659.45/267.57
Avg. Daily Volume
0.82M
Return %
Stock
S&P 500
1 year
(20.41)
(6.01)
3 years
141.08
39.24
5 years
308.95
63.25
Scale: |
High
Low
10.91
6.17
10.02
1.36
8.96
2.62
14.47
8.21
16.91
6.75
15.48
8.64
35.97
13.69
58.32
28.09
103.29
53.30
96.38
47.92
88.80
42.62
152.14
51.04
232.00
107.44
456.23
182.07
659.45
318.45
539.06
267.57
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
0.08
0.16
0.33
0.67
0.85
1.16
1.45
2.25
3.45
5.04
6.86
8.33
11.70
16.20
20.41
25.26
26.54
Earnings per share
(1.71)
(1.62)
(1.87)
(1.21)
(0.97)
(0.68)
(0.79)
(0.42)
(0.30)
(0.72)
(0.78)
(0.58)
(1.44)
1.11
5.23
1.59
2.18
FCF per share
(1.73)
(1.29)
(1.35)
(0.96)
(0.87)
(0.58)
(0.62)
(0.08)
0.10
0.20
0.01
0.30
0.64
1.48
2.93
0.55
0.97
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.12
0.12
0.08
0.07
0.12
0.12
0.14
0.11
0.22
0.42
0.67
0.76
0.76
1.98
2.11
4.01
4.03
Book Value per sh.
2.09
0.25
(1.31)
(0.42)
1.07
1.59
1.12
1.18
1.86
2.77
3.39
4.86
7.52
9.69
19.35
23.23
22.12
Comm.Shares outs.
27
28
29
44
57
66
69
71
75
80
84
86
88
91
94
97
97
Avg. annual P/E ratio
(9.0)
(5.2)
(3.3)
(4.9)
(11.6)
(19.2)
(15.0)
(54.1)
(139.2)
(104.1)
(93.7)
(117.6)
(67.6)
135.9
65.3
291.0
143.8
P/E to S&P500
(0.5)
(0.3)
(0.2)
(0.1)
(0.6)
(1.2)
(1.0)
(3.2)
(7.7)
(5.2)
(4.2)
(5.0)
(2.7)
5.6
1.7
9.7
5.5
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
2
5
10
30
49
76
100
160
259
402
573
719
1,032
1,476
1,927
2,448
2,572
Operating margin
(2,273.0)%
(1,008.8)%
(537.0)%
(154.4)%
(93.1)%
(58.8)%
(55.8)%
(18.1)%
(8.3)%
(14.2)%
(11.1)%
(5.9)%
(18.1)%
9.6%
15.5%
10.9%
10.5%
Depreciation (m)
3
3
4
2
2
4
7
7
8
11
15
16
29
49
67
102
118
Net profit (m)
(47)
(46)
(55)
(54)
(55)
(45)
(55)
(30)
(22)
(58)
(66)
(50)
(127)
101
494
154
211
Income tax rate
- -
- -
- -
- -
- -
- -
2.3%
- -
(0.4)%
(0.2)%
(1.1)%
(3.3)%
(0.5)%
3.0%
(119.4)%
11.0%
(39.6)%
Net profit margin
(2,147.6)%
(991.5)%
(560.9)%
(180.3)%
(113.4)%
(58.7)%
(54.6)%
(18.6)%
(8.6)%
(14.3)%
(11.4)%
(7.0)%
(12.3)%
6.8%
25.6%
6.3%
8.5%
Working capital (m)
52
59
17
18
51
90
58
61
105
164
178
606
1,477
1,609
2,811
2,964
3,035
Long-term debt (m)
2
61
61
46
- -
- -
7
5
2
- -
- -
328
1,010
1,060
1,823
1,898
2,121
Equity (m)
57
7
(39)
(18)
61
104
77
84
140
221
284
419
663
883
1,827
2,251
2,189
ROIC
- -
- -
- -
- -
- -
- -
(62.8)%
(32.0)%
(15.0)%
(25.4)%
(21.6)%
(4.8)%
(6.2)%
7.8%
18.5%
1.6%
2.2%
Return on capital
(72.2)%
(59.4)%
(124.4)%
(96.9)%
(69.5)%
(37.1)%
(52.5)%
(23.6)%
(11.6)%
(19.6)%
(15.9)%
(4.0)%
(5.4)%
6.9%
7.2%
1.5%
1.4%
Return on equity
(82.0)%
(644.8)%
142.9%
290.2%
(90.5)%
(42.8)%
(70.8)%
(35.4)%
(16.0)%
(26.0)%
(23.1)%
(12.0)%
(19.2)%
11.5%
27.0%
6.8%
9.6%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(8.8)%
(5.5)%
(37.7)%
(22.7)%
Capital Structure
28 Apr · 2022 | Q1
All numbers in millions
Total liabilities
$ 2,868
Total assets
$ 5,057
Long-term debt
$ 2,121
Cash and equiv.
$ 716
Goodwill
$ 27
Retained earnings
$ 236
Common stock
97
Enterprise Value
$ 29,010
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,533
2,708
2,730
Receivables
286
429
514
Inventory
120
235
357
Other
30
425
689
Current assets
1,969
3,425
3,684
Acc. Payable
102
163
- -
Debt due
14
17
40
Other
244
434
680
Current liabilities
360
614
720
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
27.06%
36.06%
43.27%
Cash flow
(80.84)%
70.08%
563.78%
Earnings
(68.80)%
73.27%
41.16%
Dividends
- -
- -
- -
Book value
23.24%
55.35%
47.91%
Insider Trading
Type
Shares
Date
Pacelli Steven Robert
Sale
250
05/24/22
Topol Eric
Award
988
05/20/22
Skyler Jay S
Award
969
05/20/22
Altman Steven R
Award
979
05/20/22
Augustinos Nicholas
Award
994
05/20/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
405
452
501
569
1,927
2021
505
595
650
698
2,448
2022
629
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.21
0.49
0.76
3.76
5.23
2021
0.42
0.65
0.73
(0.21)
1.59
2022
1.00
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Kevin Sayer
Full-time employees:
6,300
City:
San Diego
Address:
6340 Sequence Dr
IPO:
Apr 14, 2005
Website:
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.